Faron Pharmaceuticals Oy (LON:FARN – Get Free Report)’s stock price hit a new 52-week low during trading on Wednesday. The company traded as low as GBX 30.06 and last traded at GBX 32.25, with a volume of 74,224 shares. The stock had previously closed at GBX 31.50.
Faron Pharmaceuticals Oy Stock Performance
The business has a fifty day simple moving average of GBX 36.45 and a two-hundred day simple moving average of GBX 56.95. The company has a debt-to-equity ratio of 154.15, a current ratio of 2.40 and a quick ratio of 1.09. The company has a market cap of £65.43 million, a PE ratio of -2.80 and a beta of 1.12.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Featured Articles
- Five stocks we like better than Faron Pharmaceuticals Oy
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
- Amkor’s Mobile Business Is Slowing, But Its AI Ambitions Aren’t
- Want to Own a Piece of Professional Sports? This ETF Could Be Your Ticket
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
